<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351529</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_COVID-19</org_study_id>
    <nct_id>NCT04351529</nct_id>
  </id_info>
  <brief_title>Austrian COVID-19 Registry</brief_title>
  <official_title>Austrian COVID-19 Registry (AGMT_COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AGMT_COVID-19 Registry is designed as multicenter observational cohort of patients, that&#xD;
      are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing&#xD;
      to participate.&#xD;
&#xD;
      Due to the non-interventional nature of the AGMT_COVID-19 registry, only routine data, which&#xD;
      has already been recorded in the patient's medical chart, is transferred to the eCRF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute&#xD;
      respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified at the end&#xD;
      of 2019 in Wuhan, the capital of Hubei province in central China, and has since spread&#xD;
      globally.&#xD;
&#xD;
      There are currently no authorised vaccines or treatments in the EU (European Union) to&#xD;
      prevent or treat novel coronavirus disease (COVID-19) specifically or any other&#xD;
      coronaviruses.&#xD;
&#xD;
      The AGMT_COVID-19 Registry is designed as multicenter observational cohort of patients, that&#xD;
      are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing&#xD;
      to participate.&#xD;
&#xD;
      Due to the non-interventional nature of the AGMT_COVID-19 registry, only routine data, which&#xD;
      has already been recorded in the patient's medical chart, is transferred to the eCRF.&#xD;
      Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and&#xD;
      dose reductions/escalations, and response assessments shall be exclusively based on the&#xD;
      risk/benefit estimation of the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Documentation of natural course and the therapeutic landscape of patients with COVID-19.</measure>
    <time_frame>2 years</time_frame>
    <description>Due to the non-interventional nature of the AGMT_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infectious Disease</condition>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The AGMT_COVID-19 Registry is designed as multicenter observational cohort of patients,&#xD;
        that are tested positive for SARS-CoV-2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  Positive test for SARS-CoV-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Due to the non-interventional design of the registry there are no specific exclusion&#xD;
             criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IIIrd Medical Department, Private Medical University Hospital Salzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Wolkersdorfer, Dr.</last_name>
    <phone>+43 662 6404411</phone>
    <email>d.wolkersdorfer@agmt.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Esmaeilzadeh-Leithner, MSc.</last_name>
    <phone>+43 662 6404413</phone>
    <email>s.leithner@agmt.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Winder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz, Med. Campus III., Klinik für Lungenheilkunde / Pneumologie</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernd Lamprecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IIIrd Medical Department, Private Medical University Hospital Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Greil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KH Zams: Innere Medizin Internistische Onkologie und Hämatologie</name>
      <address>
        <city>Zams</city>
        <zip>6511</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ewald Wöll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

